Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

ABSTRACT

Objective: To report outcomes of pregnancies that occurred during the fingolimod clinical development program.

Methods: Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined as fingolimod treatment at the time of conception or in the 6 weeks before conception.

Results: As of October 31, 2011, 89 pregnancies were reported in completed or ongoing clinical studies, with 74 in fingolimod treatment arms. Of 66 pregnancies with in utero exposure to fingolimod, there were 28 live births, 9 spontaneous abortions, 24 elective abortions, 4 ongoing pregnancies, and 1 pregnancy with an unknown outcome (patient lost to follow-up). Two infants were born with malformations: 1 with congenital unilateral posteromedial bowing of the tibia and 1 with acrania. Elective abortions were performed for 1 case each of tetralogy of Fallot, spontaneous intrauterine death, and failure of fetal development. There were 5 cases (7.6%; 95% confidence interval 3%-17%) of abnormal fetal development in the 66 pregnancies that had in utero exposure to fingolimod. In all 5 cases, fetal exposure to the drug took place in the first trimester of pregnancy.

Conclusions: The number of patients becoming pregnant during fingolimod therapy remains small and does not permit firm conclusions to be drawn about fetal safety of fingolimod in humans. Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation. Neurology® 2014;82:1–7

GLOSSARY

CI = confidence interval; MS = multiple sclerosis.

Multiple sclerosis (MS) is predominant among women of reproductive age, in whom approximately 50% of all pregnancies are unplanned.1 Fingolimod (FTY720; Gilenya, Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that has been approved as a once-daily oral therapy for relapsing MS. Two phase II studies, 3 large-scale phase III studies, and their ongoing extension studies have indicated that fingolimod has a manageable safety profile and is generally well tolerated at the approved dose of 0.5 mg.2–6 As preclinical studies indicate a risk of fetal toxicity,7 fingolimod clinical study protocols require a negative pregnancy test at enrollment and that women of childbearing potential use reliable contraception throughout the studies. We report the outcomes of pregnancies that occurred in the fingolimod clinical development program despite these measures.

METHODS Standard protocol approvals, registrations, and patient consents. Pregnancy outcomes are reported from 9 clinical studies in patients with relapsing MS: the phase III FREEDOMS study3 (ClinicalTrials.gov number, NCT00289978 [core study] and NCT00662649 [extension]); phase III FREEDOMS II study (ClinicalTrials.gov number, NCT00355134 [core study] and NCT00774670 [extension]); phase III TRANSFORMS study with optional extension4,8 (ClinicalTrials.gov number, NCT00340834); phase II global study4,9 (ClinicalTrials.gov number, NCT00333138 [core study] and NCT00235430 [extension]); phase III open-label safety and tolerability study (ClinicalTrials.gov number, NCT01127750); phase II study in Japanese patients6 (ClinicalTrials.gov number, NCT00497791).
RESULTS As of October 31, 2011, 89 pregnancies were reported in the fingolimod clinical development program. Outcomes are summarized in table 1. Of the 11 pregnancies that occurred in patients who had been receiving placebo, 1 resulted in the birth of a healthy newborn, 1 resulted in a spontaneous abortion, and 9 were electively terminated. Of the 4 pregnancies that occurred in patients who had been receiving interferon β-1a, 2 resulted in the birth of a healthy newborn and 2 were electively terminated. Of the 74 pregnancies that occurred in patients in the fingolimod treatment arms, fingolimod was discontinued at least 6 weeks before the assumed date of conception in 8 patients; of these 8 pregnancies with no in utero fingolimod exposure, 7 resulted in the birth of healthy babies with no congenital abnormalities and 1 was electively terminated. The durations of fingolimod exposure in utero for the remaining 66 pregnancies are shown in the figure. In the 74 women in the fingolimod treatment arms who became pregnant, all prior pregnancies (if any) had no fingolimod exposure.

In the 66 pregnancies which in utero exposure to fingolimod occurred, there were 28 reported live births (42%; 95% CI, 30%–55%), 9 spontaneous abortions (14%; 95% CI, 6%–24%), 24 elective abortions (36%; 95% CI, 25%–49%), 4 pregnancies that were ongoing (6%; 95% CI, 1.7%–15%) at the time of this report, and 1 pregnancy (1.5%; 95% CI, 0.04%–8%) with an unknown outcome (patient lost to follow-up). The duration of in utero fingolimod exposure in the majority of live births was estimated to be >8 weeks to ≤12 weeks (figure). The estimated duration of in utero

Table 1 Pregnancy outcomes in the fingolimod clinical development program (as of October 31, 2011)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Delivery of newborn</th>
<th>Spontaneous abortion</th>
<th>Elective abortion</th>
<th>Ongoing</th>
<th>Unknown</th>
<th>Total, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fingolimod group</td>
<td>35 (24)</td>
<td>9</td>
<td>25 (4)</td>
<td>4</td>
<td>1</td>
<td>74</td>
</tr>
<tr>
<td>In utero exposure to fingolimod</td>
<td>28 (24)</td>
<td>9</td>
<td>24 (4)</td>
<td>4</td>
<td>1</td>
<td>66</td>
</tr>
<tr>
<td>Placebo</td>
<td>1</td>
<td>1</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
<tr>
<td>Interferon β-1a</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>38</td>
<td>10</td>
<td>36</td>
<td>4</td>
<td>1</td>
<td>89</td>
</tr>
</tbody>
</table>

*In most cases of abortion (spontaneous or elective), information on the fetus was not available.

†Pregnancy ongoing as of October 31, 2011.

‡Patient lost to follow-up.

§Congenital unilateral posteroserial bowing of the tibia (n = 1) and acrania (n = 1).

¶Tetralogy of Fallot (n = 1); ectopic/tubal pregnancy (n = 1); intrauterine death (n = 1); pregnancy not developing per standard (n = 1).

∥Fingolimod exposure in utero was defined as fingolimod treatment at the time of conception or within 6 weeks prior to conception. The date of conception was estimated as 2 weeks after the last menstrual period.
Fingolimod exposure in the majority of elective abortions was >4 weeks to ≤8 weeks, and in the majority of spontaneous abortions was >4 weeks to ≤12 weeks (figure). There were 5 pregnancies with >12 weeks of in utero exposure to fingolimod; 1 was still ongoing and 4 resulted in the birth of healthy babies with no congenital abnormalities. In most cases of abortion (elective or spontaneous), information on the fetus was not available. Follow-up data beyond birth are not available.

Overall, 37 pregnancies (excluding ongoing pregnancies, an unknown outcome [patient lost to follow-up], and the 24 elective abortions) had a known outcome. One of the elective abortions also had a known congenital abnormality of tetralogy of Fallot. Of the 37 pregnancies, 9 (24%; 95% CI 12%–41%) resulted in spontaneous abortion, 26 (70%; 95% CI 53%–84%) in delivery of healthy babies with no congenital abnormalities, and 2 (5%; 95% CI 0.7%–18%) in delivery of newborns with a congenital abnormality; the 2 congenital abnormalities that occurred were 1 female baby with congenital unilateral (right leg) posteromedial bowing of the tibia and 1 baby with acrania (absence of the cranium). The newborn with congenital unilateral posteromedial bowing of the tibia was born prematurely in the 35th week and was otherwise healthy. The mother had received fingolimod 0.5 mg for approximately 7 months before becoming pregnant.

Fingolimod was discontinued 17 days after conception, yielding an estimated in utero exposure of 8.6 weeks (table 2). The case of acrania was detected in utero by

### Table 2

<table>
<thead>
<tr>
<th>Pregnancy outcome/abnormality</th>
<th>Estimated duration of fingolimod exposure in utero, wk (d)</th>
<th>Fingolimod exposure in utero was defined as fingolimod treatment at the time of conception or within 6 weeks prior to conception. In utero exposure was calculated as date of last fingolimod dose + 6 weeks or date of abortion (whichever was earlier) – date of conception + 1 day. The date of conception was estimated as 2 weeks after the last menstrual period. <em>All percentages are calculated as n/66.</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Delivery of newborn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unilateral posteromedial bowing of the tibia</td>
<td>8.6 (60)</td>
<td></td>
</tr>
<tr>
<td>Acrania</td>
<td>9.0 (63)</td>
<td></td>
</tr>
<tr>
<td>Elective abortion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetralogy of Fallot</td>
<td>10.4 (73)</td>
<td></td>
</tr>
<tr>
<td>Intrauterine death</td>
<td>5.0 (35)</td>
<td></td>
</tr>
<tr>
<td>Ectopic/tubal pregnancy</td>
<td>5.7 (40)</td>
<td></td>
</tr>
<tr>
<td>Pregnancy not developing per standard</td>
<td>11.1 (78)</td>
<td></td>
</tr>
</tbody>
</table>

*a*Fingolimod exposure in utero was defined as fingolimod treatment at the time of conception or within 6 weeks prior to conception. In utero exposure was calculated as date of last fingolimod dose + 6 weeks or date of abortion (whichever was earlier) – date of conception + 1 day. The date of conception was estimated as 2 weeks after the last menstrual period.
ultrasound in a woman who had received fingolimod 0.5 mg for >3 years prior to becoming pregnant. Fingolimod was discontinued 3 weeks after conception, yielding an estimated in utero exposure of 9.0 weeks (table 2). The newborn was delivered prematurely by caesarean section at 7 months and died 2 days later. The patient’s obstetric history included 3 healthy births, 1 ectopic pregnancy (1997), and 1 spontaneous abortion (2006). No other risk factors (including smoking, alcohol consumption, drug/substance abuse, environmental/occupational risks, infection, hypertension, diabetes, familial disorders) were identified that could have affected the outcome of the pregnancy.

The majority of elective abortions were reported to be due to the patient’s personal choice. In 4 cases, the abortion was reported to be due to an abnormality of the fetus or of the pregnancy: tetralogy of Fallot (n = 1, see above), ectopic/tubal pregnancy (n = 1), intrauterine death (n = 1), and pregnancy not developing per standard (stopped in evolution; n = 1). The duration of in utero exposure to fingolimod in these 4 elective abortions ranged from 5 to 11 weeks (table 2). The case of tetralogy of Fallot was reported in a patient who had been receiving fingolimod 1.25 mg for approximately 9 months before becoming pregnant. In the 2 months prior to detection of the pregnancy, the patient received the following concomitant medications: imacillin (for 10 days), swine flu inoculation, and duroferon (for approximately 6 weeks). The patient’s obstetric history included 2 pregnancies resulting in healthy babies and 1 elective abortion. Fingolimod was discontinued approximately 1 month after conception, leading to an estimated 10.4 weeks of in utero exposure (table 2). Ultrasound at 18 weeks revealed tetralogy of Fallot (partial ventricular septal defect, overriding aorta, slight right ventricular hypertrophy, pulmonary artery stenosis) and an elective abortion was performed at week 19. Chromosomal tests of the fetus for trisomy 21 and 22q11 deletion were negative.

**DISCUSSION**

There is no evidence that MS increases the risk of spontaneous abortion or congenital abnormalities. Given that the incidence of MS peaks at about 30 years of age and is greater in women than in men, pregnancy issues are highly relevant and concern is raised regarding the potential impact of treatments for MS in the mother on fetal outcomes. Based on preclinical data, fingolimod has been found to have a teratogenic effect (persistent truncus arteriosus, ventricular septal defect) in rats, while studies in rabbits found excess fetal loss that precluded assessment of teratogenicity. In rats, the highest no-effect dose was less than the recommended human dose of 0.5 mg/day on a body surface area (mg/m²) basis; in rabbits, the no-effect dose was approximately 20 times the recommended human dose on an mg/m² basis. Furthermore, the receptor family modulated by fingolimod (sphingosine 1-phosphate receptor), particularly S1P₁, is known to be involved in vascular formation during embryogenesis. For these reasons, strict contraception was mandated during exposure to fingolimod in female patients participating in the clinical trial program and continues to be mandatory in the post-approval setting. However, a number of pregnancies did occur in female patients receiving fingolimod despite these precautions. A formal drug–drug interaction study of fingolimod and oral contraceptive medication did not show evidence of any interaction that could have resulted in less effective contraception. Therefore, the occurrence of pregnancies likely reflects failure to observe preventive measures rigorously. A total of 89 pregnancies were reported (74 fingolimod, 11 placebo, and 4 interferon β-1a). The total fingolimod exposure for women up to 50 years of age was 10-fold that of placebo involving 3-fold as many patients.

Of the 66 pregnancies in which in utero exposure to fingolimod occurred, 24 were electively terminated, 1 was lost to follow-up, and 4 were ongoing, leaving 37 pregnancies. Of these, three-quarters resulted in live births and 9 (24%; 95% CI 12%–41%) resulted in spontaneous abortion. In the general population, spontaneous abortion is reported to occur in 15%–20% of known pregnancies, and major birth defects to occur in 4%–8% of pregnancies. The rate of spontaneous abortion with fingolimod may slightly exceed expected rates, but the number of cases is relatively small and CIs overlap expected rates; our estimate is also calculated conservatively, given that we include only the 37 pregnancies with potential to go to term (i.e., those that resulted in live births or spontaneous abortions) in the denominator.

Of the 2 cases of malformation that occurred among the live births, 1 infant was born with congenital unilateral posteromedial bowing of the tibia following in utero exposure to fingolimod. The developmental etiology of this disorder is unknown, but most authors believe the occurrence is secondary to mechanical factors including abnormal fetal positioning. It is, therefore, considered unlikely that this localized lesion resulted from exposure to fingolimod during embryogenesis. The typical natural history of the bowing is spontaneous resolution, especially during the first 6 months, but some patients require surgical intervention to correct residual bowing, limb-length inequality, or ankle deformity. The other malformation among the live births was a case of acrania, a rare (1/10,000 births in the general population) neural tube defect with various etiologies (including chromosomal abnormalities, single gene mutations, and maternal exposure to teratogens).

In addition, 3 of the elective abortions were carried out because of fetal developmental abnormality:
1 major congenital malformation (tetralogy of Fallot; ~1/2,500 births in the general population), 1 spontaneous intrauterine death (cause unknown), and 1 failure of fetal development (further information not available). The majority of other elective abortions resulted from patients’ personal reasons and occurred during the first trimester; information on the fetus was unknown in most cases.

Pooling fetal abnormalities from those with elective abortions and those with live births, there were 5 (7.6%; 95% CI 3%–17%) cases of abnormal fetal development in the 66 pregnancies that had in utero exposure to fingolimod. In all 5 cases, fetal exposure to the drug took place in the first trimester of pregnancy.

One of these abnormalities, acrania, is particularly rare, and the relationship to drug must be considered as possible even though the case was isolated. It has been hypothesized that neural tube defects, of which acrania is a severe form, may have a vascular basis. In animal studies, neural tube closure was severely disturbed in mouse embryos that lacked either S1P1 or the 2 enzymes that are required to convert sphingosine to sphingosine 1-phosphate.

The number of patients in the fingolimod treatment arms who became pregnant after discontinuing fingolimod was small (n = 8), thus precluding any meaningful comparison being made between this group and those who became pregnant while exposed to fingolimod.

Previous investigations of pregnancy outcomes following in utero exposure to MS disease-modifying drugs generally report no increase in the rates of spontaneous abortions or congenital malformations. In a recent study, 425 pregnancies had in utero exposure to interferon β with 324 healthy births, 5 congenital abnormalities (4 live births, 1 stillbirth), and 49 spontaneous abortions. A similar pattern was observed in an earlier study in which 41 pregnancies were exposed in utero to interferon β, resulting in 20 healthy offspring, 1 congenital anomaly (hydrocephalus), 1 fetal death, and 8 spontaneous abortions. Two further studies in which in utero exposure to interferon β occurred (n = 88, n = 69) reported no significant drug-related congenital defects. In contrast, 1 small study of 23 pregnancies in patients treated with interferon β reported a higher rate (39.1%) of spontaneous abortions and stillbirths in those with in utero exposure than in healthy controls (5%). Two investigations into the implications of exposure to glatiramer acetate during pregnancy (n = 11, n = 9) reported no drug-related pregnancy complications, whereas 1 (n = 31) reported 2 malformations (club feet and atroventricular canal). A recent study of 35 pregnancies in which in utero exposure to natalizumab occurred reported 28 healthy infants, 1 case of hexadactyly, and 5 spontaneous abortions.

All labels worldwide for fingolimod state that women of childbearing potential should be advised to take effective contraceptive measures during fingolimod therapy and, given the half-life of the compound, for at least 2 months after stopping therapy. Fingolimod is included in the US Food and Drug Administration’s pregnancy category C (definition: animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and well-controlled studies in pregnant women, and the benefits of treatment in pregnant women may be acceptable despite its potential risks). A multinational pregnancy exposure registry has been set up, which is a prospective observational study aimed at enrolling pregnant women exposed to fingolimod worldwide in order to collect prospective data on pregnancy outcomes (for further information or enrollment in the registry, contact gpr@outcome.com; +1-877-598-7237 [toll-free, North America]; +800-688-266-37 [toll-free outside North America]).

As the number of patients becoming pregnant during fingolimod therapy remains low, firm conclusions about the safety of fingolimod during pregnancy are not possible. However, the 5 cases of abnormal fetal development seen among 66 pregnancies with in utero fingolimod exposure, together with preclinical data showing teratogenicity, indicate a potential risk of treatment-related developmental abnormalities. It is therefore strongly recommended to patients and physicians that pregnancy be avoided by effective contraception during treatment with fingolimod in female patients of childbearing potential. Furthermore, the occurrence of more than 80 pregnancies in the fingolimod clinical development program despite the stipulation of double contraceptive measures highlights an educational need for both physicians and patients. A fingolimod pregnancy registry has been established to record data on pregnancy outcomes in women exposed to fingolimod should they inadvertently become pregnant.

**AUTHOR CONTRIBUTIONS**
All authors were involved in analysis and interpretation of the data and drafting and revising the manuscript for content. G. Karlsson, G. Francis, G. Koren, W. Collins, and J.A. Cohen were involved in study design and concept. G. Karlsson, X. Zhang, J.A. Cohen, and W. Collins were involved in acquisition of data. G. Karlsson and G. Francis were involved in statistical analysis. G. Francis, X. Zhang, and J.A. Cohen were involved in study supervision or coordination.

**ACKNOWLEDGMENT**
The authors thank the patients who participated in the study, the study site personnel, and Oxford PharmaGenesis Ltd. (funded by Novartis Pharma AG) for facilitating author discussion, collating author comments, and formatting the manuscript according to journal requirements.

**STUDY FUNDING**
Supported by Novartis Pharma AG, Basel, Switzerland.
DISCLOSURE

G. Karlsson is an employee of Novartis. G. Francis is an employee of Novartis. G. Koren received consulting fees from Duchesnay, Novartis, and Bayer. P. Heinig is an employee of Novartis. X. Zhang is an employee of Novartis. J. Cohen has received reimbursement of travel costs and fees for participation in study steering committees from Novartis. He has received consultancy fees from Biogen Idec, Elan, Five Prime Therapeutics, Eli Lilly, Novartis, Teva, and Vaccines. J.A. Cohen has also received payment for speaker services from Novartis and Biogen Idec. L. Kappos has received research support to his institution for board membership, consultancy or speaking, or grants, in the last 3 years, from Acrislon, Advancell, Alnyxne, Bayer, Bayifll, Biogen Idec, BioMarin, CSL Behring, Eli Lilly, European Union, Gennab, GeNeuro, Gianni Rubinato Foundation, Glenmark, Merck Serono, MediciNova, Mitsubishi Pharma, Novartis, Novartis Research Foundation, Novo Nordisk, Peptimmune, Roche, Roche Research Foundation, Santhera, Sanofi Aventis, Swiss MS Society, Swiss National Research Foundation, Teva, UCB, and Wyeth. W. Collins is an employee of Novartis. Go to Neuronology.org for full disclosures.

Received October 23, 2012. Accepted in final form October 14, 2013.

REFERENCES


